<DOC>
	<DOCNO>NCT00149240</DOCNO>
	<brief_summary>The main purpose study determine effectiveness safety one dose botulinum toxin type A ( Dysport ) associate rehabilitation treatment pain control patient type back pain call primary myofascial pain syndrome .</brief_summary>
	<brief_title>Botulinum Toxin Type A ( Dysport ) Associated With Rehabilitation Treatment Patients With Primary Myofascial Pain Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Somatoform Disorders</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Patients primary myofascial pain syndrome cervical dorsal localization , less two year length , must diagnose evidence `` trigger point '' conventional treatment oral analgesia , rehabilitation local anesthesia clinically successful 15 day . Punctuation 4cm 10cm visual analog scale . Previous positive response ( selflimited reduction less 15 day pain ) anaesthetic infiltration trigger point . Patients diagnose fibromyalgia spread pain . Patients receive previously botulinum toxin . Patients receive anesthetic injection trigger point within month visit . Patients receive corticosteroids injection trigger point within three month selection visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2007</verification_date>
	<keyword>DYSPORT</keyword>
	<keyword>botulinum toxin A</keyword>
	<keyword>myofascial pain syndrome</keyword>
</DOC>